ViiV Says Latest Data Back Two-Drug Approach, Plans Year-End Fostemsavir Filing

ViiV Healthcare research head tells Scrip she expects Dovato’s latest data presentation should boost the two-drug regimen’s uptake, and that the AIDS-fighter plans a US FDA filing of its investigational candidate fostemsavir before end-2019 following good Phase III BRIGHTE results.

HIV virus
Dovato and fostemsavir Data presented at International AIDS Society Meeting in Mexico • Source: Shutterstock

GlaxoSmithKline PLC’s HIV medicines unit ViiV Healthcare , which represents about 20% of GSK's sales, believes its two-drug therapy Dovato (dolutegravir/lamivudine) will see better acceptance and a boost in its sales following positive data presented at this week’s International AIDS Society meeting in Mexico City.

And good results also presented at the AIDS conference from ViiV’s Phase III BRIGHTE study demonstrated strong efficacy of investigational...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By 

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By 

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.